United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$272.69 USD
+2.91 (1.08%)
Updated May 15, 2024 04:00 PM ET
After-Market: $272.77 +0.08 (0.03%) 4:18 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 501 - 520 ( 587 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Pulling A Rabbit Out Of Its Hat: FDA Accepts Rapid Resubmission Of Oral Treprostinil NDA With Class 1 Review And March 31 PDUFA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Revenues And Earnings Beat (Again) And We Project Consistent Double Digit Growth Through 2016. Reiterate OUTPERFORM and $91 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Preview: We Believe Street Estimates Are Achievable;
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Oral Treprostinil Receives CRL Instead of Approval; We Recommend Buying On Weakness; Reiterate OUTPERFORM And $91 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
LIFE SCIENCES - The Week Ahead in Life Sciences - Upcoming Events for the Week of October 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
We Believe Self-Injected Treprostinil Could Be Important For Life-Cycle Management;
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
September and Remaining 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2:12 Revenues And Earnings Beat (Again; 2012 Revenue Guidance Reconfirmed-Reiterate OUTPERFORM and $91Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Corporate Update: We Believe the Company Can Address Three Key Issues Causing Overhang on the Stock
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L